I've been following Osaris(osir) for the last 2 years ,at one...

I've been following Osaris(osir) for the last 2 years ,
at one time their market cap was more then a Billion ,
they have had issues with failed diabetes trials and misleading bone data,in any other market they would have been decimated but they are supported by capital that is betting on better outcomes .I wish them luck , nothing could be better in the regenerative space then a success storey as the big investors are weary of new technologies and continues to watch and wait.
Osaris is generally regarded has having a less potent Mesenchymal cells then Msb's MPC.

Regarding published papers could someone tell me the average time between the completion of trials and the publication of data in journals ?

Regarding post post-hoc analysis,why would you disregard any data , Sildenafil (Viagra)was initially developed for angina but post-hoc data revealed its superb benefits for patients with erectile dysfunction and pulmonary hypertension,so do you dismiss this data because it was "post hoc"?.....it just doesn't make sense !!

Researcher are not created equal ,though most are ethical there are egos out there with agendas .In my humble opinion the market is your best guide in the long term ,there are 18.2 mil shorted msb shares ,mostly Macquarie clients,
that actually represents more then 10% of traded stock,
I believe that we are on the verge of a fundamental shift in Msb's fortunes (any one that has read my post would knows that i am the original mesophile and am hooked on MPC so DYOR)and the shorting will result in a squeeze and the turbo charging of the share price .....so i"m ask you Macquarie "Well, do you feel Lucky. Well do ya, Punk ?"(apologies to Dirty Harry )
Its great to see a vibrant discussion regarding the regenerative medical space .

"I POST THEREFORE I AM "khunfoti 2012